Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTE NASDAQ:GXGX NYSE:MBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$7.36+8.7%$8.65$56.35▼$105.00$213.33M0.9512,438 shs186,080 shsGXGXGX Acquisition$3.48+0.6%$6.61$7.73▼$12.58$125.06M0.17743,827 shs26,513 shsMBXMBX Biosciences$14.72+11.4%$12.21$4.81▼$27.50$443.78MN/A329,571 shs577,730 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics+8.71%-1.74%-16.46%+0.20%-87.77%GXGXGX Acquisition+0.58%+7.41%+62.62%+70.59%+25.63%MBXMBX Biosciences0.00%+21.05%+20.75%+31.90%+1,471,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGXGXGX AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AMBXMBX Biosciences2.5746 of 5 stars3.50.00.00.03.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics 0.00N/AN/AN/AGXGXGX Acquisition 0.00N/AN/AN/AMBXMBX Biosciences 3.00Buy$37.63155.60% UpsideCurrent Analyst Ratings BreakdownLatest GXGX, MBX, and AVTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/5/2025MBXMBX BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.007/16/2025MBXMBX BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.00(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/AGXGXGX AcquisitionN/AN/AN/AN/A$0.14 per shareN/AMBXMBX BiosciencesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%N/AGXGXGX Acquisition-$49.26MN/A0.00∞N/AN/A-985.20%-6.02%N/AMBXMBX BiosciencesN/A-$4.54N/AN/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AGXGXGX AcquisitionN/AN/AN/AN/AN/AMBXMBX BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A8.788.78GXGXGX AcquisitionN/A0.020.02MBXMBX BiosciencesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/AGXGXGX Acquisition61.65%MBXMBX BiosciencesN/AInsider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics24.90%GXGXGX AcquisitionN/AMBXMBX Biosciences52.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableGXGXGX AcquisitionN/A35.94 millionN/ANot OptionableMBXMBX Biosciences3633.59 millionN/AN/AGXGX, MBX, and AVTE HeadlinesRecent News About These CompaniesJefferies Financial Group Initiates Coverage on MBX Biosciences (NYSE:MBX)August 17 at 9:15 AM | marketbeat.comHead-To-Head Survey: MBX Biosciences (MBX) versus Its CompetitorsAugust 16 at 3:19 AM | americanbankingnews.comA Glimpse of MBX Biosciences's Earnings PotentialAugust 14 at 11:19 AM | benzinga.comMBX Biosciences, Inc. (NYSE:MBX) Given Consensus Recommendation of "Buy" by AnalystsAugust 14 at 2:27 AM | marketbeat.comMBX Biosciences, Inc. (NYSE:MBX) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 13, 2025 | americanbankingnews.comMBX Biosciences Reports Progress and Financial StabilityAugust 11, 2025 | tipranks.comMBX Biosciences (NYSE:MBX) Earns Outperform Rating from Analysts at MizuhoAugust 8, 2025 | americanbankingnews.comMBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate HighlightsAugust 7, 2025 | globenewswire.comMBX Biosciences (NYSE:MBX) Coverage Initiated at MizuhoAugust 6, 2025 | marketbeat.comMizuho Initiates Coverage of MBX Biosciences (MBX) with Outperform RecommendationAugust 5, 2025 | msn.comTD Asset Management Inc Raises Stock Holdings in MBX Biosciences, Inc. (NYSE:MBX)August 5, 2025 | marketbeat.comMBX Biosciences Inc. (MBX) Stock Price Today - WSJAugust 2, 2025 | wsj.comMBX Biosciences (NYSE:MBX) Shares Up 15.7% - What's Next?July 26, 2025 | marketbeat.comMBX Biosciences, Inc. (NYSE:MBX) Receives Average Rating of "Buy" from AnalystsJuly 19, 2025 | marketbeat.comOppenheimer Initiates Coverage of MBX Biosciences (MBX) with Outperform RecommendationJuly 17, 2025 | msn.comMBX Biosciences Inc Executives - MorningstarJune 25, 2025 | morningstar.comMMBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development - MorningstarJune 24, 2025 | morningstar.comMMBX Biosciences Inc Chart - MorningstarJune 24, 2025 | morningstar.comMMBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical DevelopmentJune 23, 2025 | globenewswire.comMBX Biosciences Submits IND for Obesity TreatmentJune 16, 2025 | tipranks.comMBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of ObesityJune 16, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGXGX, MBX, and AVTE Company DescriptionsAerovate Therapeutics NASDAQ:AVTE$7.36 +0.59 (+8.71%) As of 08/15/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.GX Acquisition NASDAQ:GXGXGX Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2018 and is based in New York, New York.MBX Biosciences NYSE:MBX$14.72 +1.51 (+11.43%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$14.50 -0.23 (-1.53%) As of 08/15/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Is Reddit Stock Too Hot, or Just Right? Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access